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Expression of granzyme A and B proteins by cytotoxic lymphocytes
involved in acute renal allograft rejection. Granzymes A and B are
serine-proteinases stored in the granules of activated cytotoxic T-lympho-
cytes and natural killer (NK) cells. Expression of granzymes in tissues can
be used as an activation marker for cytotoxic cells. Using mAbs specific for
human granzyme A or B in immunohistochemical staining techniques we
investigated expression of granzyme A and B by lymphocytes infiltrating
acutely rejected renal allografts. Twelve core needle biopsies were taken
from ten different patients during an episode of acute rejection. Eleven
biopsies contained high numbers of granzyme A and B positive lympho-
cytes infiltrating tubular epithelium, and vascular and glomerular struc-
tures. In one patient infiltrating lymphocytes did not express granzyme A
and only low amounts of granzyme B. No correlation was found between
the number of granzyme positive cells and the severity of the rejection as
classified by conventional histological criteria. In one tissue specimen from
a patient with a renal allograft without signs of rejection, the number of
granzyme positive cells was much lower compared to that of the transplant
group. In spite of the presence of a marked inflammatory infiltrate, no
granzyme positive cells were detected in renal biopsies from patients with
various inflammatory, not transplant-related, renal diseases. Phenotypic
analysis showed that granzymes A and B were expressed by CD56 NK
cells and CD3 cells, representing cytotoxic T-Iymphocytes. Thus, this
study demonstrates that granzyme A and B protein-expressing lympho-
cytes infiltrate the kidney allografts during an acute cellular rejection but
not in several other inflammatory renal diseases. The appearance of these
granzymes could therefore provide a means to predict a rejection episode
or to monitor the efficacy of immunosuppressive therapy.
Despite consideral improvement of immunosuppressive medi-
cation, in particular the introduction of cyclosporin A, renal
transplantation is still confronted with several complications
which may affect graft functioning. Apart from surgical and
urological complications, early allograft dysfunction may result
from several processes, such as cyclosporin A toxicity, acute
tubular necrosis (ATN) or immunologic rejection of the allograft.
A main reason for allograft rejection is the presence of incom-
patible major histocompatibility (MHC) class I and II antigens on
the grafted tissue, which are the major targets for an immunolog-
ical attack. These so-called allo-MHC antigens are presented to
CD4 T cells, which subsequently become activated and induce
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clonal expansion of antigen activated CD4 and CD8 cells
[reviewed in 1].
Damage of the allograft tissue is frequently mediated by
activated cytotoxic cells. Several cell populations may mediate
cellular cytotoxicity, including allospecific CD3 CD8 cytotoxic
T lymphocytes (CTL), CD3CD4 T helper cells [1] and natural
killer (NK) cells which are involved in non-MHC restricted
cytotoxicity [2, 3]. To assess the contribution of these cell types in
renal allograft rejection, many studies have analyzed the pheno-
type of the different lymphocyte subsets present in the allograft
[4, 5]. Detection of lymphocyte infiltration in this way, however,
may not always provide information about the activation state of
these cells, although the expression of activation markers, such as
IL-2 receptor-a (CD25) and MHC class II [6, 7] or proliferation
characteristics of the lymphocytes have been used in this regard
[8].
Cytoplasmic granules of activated CTL and NK cells contain a
set of specific molecules which play a role in the destruction of
target cells. Upon recognition of the target cell, reorientation and
subsequent release of these granule contents towards the target
cell occurs [9, 10]. These contents consist of a pore forming
protein "perform" [11, 12] and a group of highly homologous
serine proteinases, termed granzymes. In humans, two granzymes,
A and B, have been characterized at the eDNA as well as at the
protein level [9, 13, 14]. The presence of both perform and
granzyme A correlates with activation and subsequent cytolytic
potential of these cells in vitro [15—17]. Recently, studies using in
situ hybridization have shown in vivo expression of granzyme and
perform mRNA by activated cytotoxic cells in murine [18—20] and
human [21—23] tissues. In biopsies from patients who had under-
gone cardiac transplantation, granzyme A and perform mRNA
positive lymphocytes were specifically associated with a rejection
episode [21]. Moreover, the granzyme B gene appeared to be
expressed in human renal allografts biopsies from patients with an
acute cellular rejection, as was assessed by a semi-quantitative
polymerase chain reaction (PCR) analysis [24].
Recently, we have described the production of two sets of
monoclonal antibodies (mAb) against human granzyme A and B,
respectively [25]. In this study we have used these mAb to detect
expression of granzyme proteins by activated cytotoxic cells in
renal allograft biopsies showing an acute cellular rejection. A
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Table 1. Clinical characteristics of the patients studied
Patient Age/Sex Tx/Bx interval Diagnosis
1 52 M 1 month ACR grade III
2 34 M 2 months ACR grade II
3 58 F 3 weeks ACR grade II
4 25 M 10 months ACR grade II; also chronic damage
5 46 M 2 weeks ACR grade I—IT
6c 40 M 3 months ACR grade I—IT
6b 40 M 6 weeks ACR grade II
6a 40 M 3 weeks ACR grade III
7 41 F 1 month ACR grade II; also chronic damage
8 60 F 3 weeks ACR grade III
9 43 M 6 months ACR grade TI—Ill
10 44 M 4 days ACR grade TI—Ill
Control s
11 69 F — Chronic pyelonephritis
12 53 M — Adenocarcinoma renis
13 36 M 4 months Focal glomerulosclerosis in renal Tx
14 56 M — Arteriosclerosis in DM I
15 64 M — Vasculitis
16 20 M — Granulomatous inflammation
17 55 M — Interstitial nephritis
Note that patient 6 was studied during 3 different rejection episodes.
For diagnosis, as determined by routine histological examination, see
Methods. TxJBx interval is the interval between time of transplantation
and time of biopsy.
double immunohistochemical staining was used to identify the
phenotype of these cytotoxic cells.
Methods
Patients
All renal allograft patients received basic immunosuppressive
drug therapy consisting of prednisolone (10 mg/day) and cyclo-
sporin A (yielding whole blood trough levels of 150 to 200
j.g/liter) orally. Twelve core needle biopsies were taken from 10
different patients during an episode of acute rejection. Rejection
was clinically defined as an insufficient improvement of renal
function, or a rise of an initially decreasing or stable serum
creatinine, with or without a decrease in urinary output and
subsequently recovery after therapy. As controls, biopsies and
nephrectomy specimens from seven patients with different renal
diseases were included (Table 1).
A portion of each tissue was fixed for three hours in a solution
containing 50 m sodium phosphate buffer, 40 m acetic acid,
60% (vol/vol) ethanol, 3% (vol/vol) formaldehyde, pH 3.8 [ac-
cording to Tellyesniczky (TEL)], and embedded in paraffin for
routine examination and immunohistochemical studies of expres-
sion of granzymes A and B. An additional part of the specimen
from six biopsies was snap frozen in liquid nitrogen for double
immunohistochemical staining. Cryostat sections (5 jrm) were
placed on poly-L-lysine coated glass slides, air dried, fixed in
aceton for 10 minutes at room temperature (RT) and stored at
—70°C until immunohistochemical analysis.
Classification
Histological diagnosis of acute cellular rejection was based on
the following parameters according to the Banff classification [26]:
"mononuclear infiltration of the interstitium; signs of tubulitis; or
vascular endothelitis." The biopsies were classified into three
categories according to the severity of the rejection: grade I, II
and III. In some cases (patients 4 and 9), these biopsies contained
elements of chronic damage, as manifested by the presence of
ischemic leasions, interstitial fibrosis or tubular atrophy. There
were no signs of vascular rejection or active cytomegalovirus
infection at the time of biopsy.
Antibodies
Monoclonal antibodies specific for human granzymes A and B,
respectively, were elicited against recombinant human granzyme
A and granzyme B proteins as described elsewhere [25]. We have
previously shown that on immunoblot the mAbs GrA-6 and
GrA-8 (both IgGi) react specifically with granzyme A, and mAb
GrB-4 (IgGi) with granzyme B from IL-2-stimulated peripheral
blood mononuclear cells. In addition, in immunofluorescense and
immunohistochemical studies, both mAbs specifically detected
human granzymes A and B in cytotoxic granules from NK cells
[25], CTL clones and activated peripheral blood lymphocytes
(manuscript in preparation). The mAbs were purified by protein
G affinity-chromatography (Pharmacia Fine Chemicals, Uppsala,
Sweden). Biotinylation of antibodies was carried out using long
chain biotinyl-N-hydroxysuccinimide ester sulfonacid (Pierce
Chemical Co., Rockford, IL, USA) according to the manufactur-
er's instructions. Fluorescein isothyocyanate (FITC)-labeling of
GrB-4 was performed essentially as described previously [27].
The following FITC-labeled mAbs were used to determine the
phenotype of the T lymphocytes: anti-Leu-4, anti-Leu-3a+b,
obtained from Becton Dickinson (San Jose, CA, USA), directed
against CD3 and CD4, respectively, and Dako-T8, obtained from
Dakopatts (Copenhagen, Denmark), directed against CD8. NK
cells were detected using mAb 733.24 against CD56 (NKH1
marker), kindly provided by Dr. E. Roosnek (Department of
Transplantation, Hospital Cantonal Genève, Switzerland). Rabbit
polyclonal antibodies against human CD3 (Dakopatts) was used
to detect T cells in paraffin embedded tissue. Biotinylated rabbit
anti-mouse Fab2 immunoglobulins, biotinylated swine anti-rabbit
Fab2 immunoglobulins, rabbit anti-FITC immunoglobulins, alka-
line phosphatase (AP)-conjugated swine anti-rabbit immuno-
globulins and horseradish (HRP)-labeled streptavidin-ABC com-
plex were all purchased from Dakopatts.
Immunohistochemical techniques
Monostaining. Paraffin embedded tissue sections (4 .tm) were
used to detect granzyme A, B and CD3 expressing cells infiltrating
the renal tissue. All incubations were performed at RT, after each
incubation step the slides were washed three times for five
minutes with phosphate buffered saline (PBS).
Paraffin sections were deparaffinized and incubated with meth-
anol containing 0.3% (vol/vol) H202 (Sigma, St. Louis, MO,
USA) for 30 minutes to inactivate endogenous peroxidase. Then,
slides were washed and treated with 10 m sodium citrate, pH 6.0,
for 10 minutes at 100°C, to enhance the immunoreactivity of the
anti-granzyme mAbs, or incubated with 0.25% (wt/vol) pepsine in
10 mM HC1 for 15 minutes at 37°C for the detection of CD3. Slides
were rinsed and pre-incubated with normal goat serum (1:10
diluted in PBS-1% (wt/vol) bovine serum albumin, PBS-B) for 10
minutes and subsequently incubated for one hour with the GrA-6,
GrB-4 mAb (both 10 xg/ml in PBS-B) or polyclonal antibodies
against CD3. Sections were washed and then incubated for 30
minutes with biotinylated rabbit anti-mouse Fab2 or biotinylated
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swine anti-rabbit Fab2 immunoglobulins, respectively [each di-
luted in PBS containing 10% (vol/vol) normal human serum
(PBS-NHS)]. Sections were washed and subsequently incubated
for 30 mm with HRP-labeied streptavidin-ABC complex, diluted
in PBS-NHS, according the manufacturer's instructions. HRP
activity was detected by incubating the slides for three minutes
with 30 mg of diaminobenzidine (Sigma) in 100 ml of PBS
containing 20 pA 30% (vol/vol) H202. As a control, sections were
incubated with an irrelevant mAb of the appropriate subclass.
Double staining. To identify the phenotype of granzyme positive
cells a sequential immunohistochemical technique was performed
on cryostat sections by combining two indirect techniques using
FITC-conjugated and biotinylated mAbs as described by van der
Loos et al [27]. Serial (5 m) cryostat sections were air dried and
fixed in acetone for 10 minutes at RT. To block endogenous
biotin, present in the renal tissue, slides were incubated with 0.5
mg/mi streptavidin (Zymed, San Fransisco, CA, USA) for 20
minutes, rinsed with PBS and incubated for another 20 minutes
with 0.1 mg/ml d-biotin (Sigma). Slides were washed, preincu-
bated with 10% (vol/vol) normal mouse serum for 10 minutes, and
then incubated for 60 minutes with FITC-conjugated mAb GrB4
or mAbs for phenotype analysis, combined with biotinylated mAb
GrA-8. After a washing step, slides were incubated with 0.3%
(vol/vol) H202, 0.1% (wt/vol) sodium azide in PBS for 20 minutes
to block the endogenous peroxidase activity. Then, slides were
incubated for 30 minutes with HRP-labeied streptavidin-ABC
complex and rabbit anti-FITC immunoglobulins diluted in PBS-
NHS. The slides were washed with 50 mrvi Tris-HC1 pH 7.6, 150
mM NaCI, and incubated with AP-conjugated swine anti-rabbit
immunoglobulins for 30 minutes. After a final wash step the
bound AP activity was detected with naphtol-AS-MX phosphate
(Sigma), and Fast Blue BB in 0.2 M Tris-HC1 pH 8.5 (20 mm, in
the dark) yielding a blue color. Endogenous AP activity was
blocked by addition of 1 m'vi levamisole to the reaction medium.
HRP activity was detected using H202 (0.1%) and 3-amino-9-
ethylcarbazole (Sigma) yielding a red color. Finally, slides were
fixed in 4% (vol/vol) formaldehyde in PBS. As a control, irrelevant
biotinylated or FITC labeled mAbs were used or the antibodies
were omitted.
Immunohistological evaluation
Every tissue section stained for granzyme A, B was scored
independently by two observers who were blinded for the clinical
data. The number of positive cells were counted per field in four
representative areas by high power field magnification (400X) (0:
<5; +: 6—25; ++: 26—50; +++: 51—100 and ++++: >100
positive cells per field).
Results
Granzyme A and B expression in allografis
In Table 1, the data profile of the 10 patients who had an
episode of acute cellular rejection is shown. From one patient
three biopsies were taken during different rejection episodes.
Besides clinical and morphological evidence for an acute cellular
rejection, biopsies from two patients (nr. 4 and 7) also showed
mild interstitial fibrosis and tubular atrophy as indication of
chronic nephropathy. As controls, biopsies or nephrectomy spec-
imens were taken from patients with various renal diseases.
Patient 13 had received a renal allograft and suffered from a
Table 2. Number of granzyme A, B or CD3 positive cells per high
power field magnification (400X)
Patient Gran A Gran B CD3
1 +++ +++ ++++
2 ++ ++ ++++
3 ++ +++ ++++
4 ND ++ ++++
5 ++ ++ ++++
6a +++ +++ ++++
6b ++++ ++++ ND
6c + +++ ++++
7 ++ ++ +++
8 ND ++ ++++
9 0 + ++++
10 ++ ++ +++
Controls
11 0 0 0
12 0 0 0
13 + + ++++
14 0 0 ND
15 0 0 ++
16 0 0 ++++
17 0 0 ++++
The number of positive cells were counted per field in four represen-
tative areas (0<5; +, 6—25; ++, 26—50; +++, 51—100 and ++++, >100
positive cells per field; ND, not determined).
recurrence of his original kidney disease, focal glomerulosclerosis.
His biopsy showed focal glomerulosclerotic changes without any
sign of rejection.
Serial tissue sections of the biopsies were examined for the
presence of granzyme A or granzyme B expressing lymphocytes
using monoclonal antibodies reacting with granzyme A or B. The
results are summarized in Table 2. In all patients showing signs of
aliograft rejection, granzyme B positive cells (10 to 200 cells per
high power field) were found to infiltrate the renal tissue.
Likewise, in nearly all biopsies granzyme A positive cells (25 to
200 cells per high power field) were found, except for patient 9
where no granzyme A positive cells were detected. In general, the
number of granzyme A positive cells was comparable with that of
granzyme B positive cells. Each of both cell populations showed a
similar distribution in the renal tissue. All allografts showed
extensive infiltration with CD3 positive lymphocytes (Table 2). No
correlation between the severity of histological changes of the
allograft and the number of granzyme A, B or CD3 positive cells
was found (Table 2). In most cases the granzyme A and B positive
cells in the allograft were scattered through the renal tissue
although clusters of these cells were also observed in all biopsies.
Granzyme positive cells were found in the interstitium, the
glomeruli, the tubular walls and in the peritubular capillaries (Fig.
1A). Figure lB shows a tubule which is infiltrated by a lymphocyte
expressing granzyme A. In Figure 1C granzyme B expressing cells
are located within the glomerulus. The intensity of the granzyme
A and B staining was variable and the granzyme expressing
lymphocytes showed a heterogenous morphology. Most granzyme
positive lymphocytes exhibited features of blasts but also some
small lymphocytes showed cytoplasmic staining for granzymes.
None or very low (patient 13) amounts of granzyme A or B
positive cells were found in the renal tissues of the control
patients, although in four patients extensive CD positive infiltra-
tions were found. Some granzyme A and B positive cells were
present in the mononuclear infiltrate found in biopsies from a
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Fig. 1. Immunoperoxidase staining ofgranzymeA (A, magnification 175)< and B, magnification 200X) and granryme B (C, magnification 500X) expressing
cells in tissue of a patient during an acute rejection episode. D. A control staining is shown using an irrelevant mAb (magnification bOX).
patient with a renal allograft although no histological evidence
was found for rejection. The number of positive cells (<10 per
high power field for granzyme A and B) and the amount of
granzymes A and B in these cells, as reflected by the staining
intensity, in this patient was much lower than the number of
granzyme positive cells found in the biopsies showing allograft
rejection (with exception of that from patient 9). Also, in this
patient no granzyme positive cells were found infiltrating the
tubules or glomeruli. One patient with a renal adenocarcinoma
(patient 12) showed granzyme A and B expressing cells infiltrating
the renal tumor, while no granzyme positive cells were detected in
the unaffected renal tissue.
Phenolypic characterization of granzyme positive cells
In six biopsies from five patients a double immunohistochemi-
cal technique was used to identify the phenotype of granzyme
expressing cells. The results are shown in Table 3. In all cases the
majority of granzyme A expressing cells expressed the NK cell
marker CD56 on their cell surface. In most patients only a few
CD4 or CD8 positive cells had detectable granzymes, except
for patient numbers 3 and 4, in whom up to 15% of the granzyme
A positive cells were CD8 (Table 3). A subset of NK cells
expresses low levels of CD8 on their surface [28]. To exclude that
this population accounted for the CD8 positive cells expressing
Table 3. Phenotype of granzyme A positive cells in renal allograft
biopsies
Patient CD3 CD4 CD8 CD56
3 <10% <5% 10% >85%
4 <15% <5% 15% >80%
5 ND <5% <5% >90%
6a ND <5% <5% >90%
6c ND <5% <5% ND
8 ND <5% <5% >90%
granzymes, we performed double staining with granzyme A and
CD3. The equal number of CD3 and CD8 granzyme expressing
cells in these biopsies indicated that the CD8 and granzyme
positive cells represented activated cytotoxic T lymphocytes. All
CD56 NK cells infiltrating the renal tissue expressed granzyme
A. In contrast, most CD8 cells did not. Figure 2 shows some
examples of these studies: granzyme A positive cells double-
stained with an anti-CD8 (Fig. 2A) or an anti-CD56 (Fig. 2B)
mAb. To determine that granzyme A and B were indeed ex-
pressed by the same cells a double staining was also performed
using a biotinylated anti-granzyme A and a FITC-labeled anti-
granzyme B mAb (Fig. 2C). Most cells positive for granzyme A
C L..
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Fig. 2. Double immunohistochemist,y staining of
g.ranzyme A expressing cells (peroxidase staining: red)
with CD8 (A, magnification 450X), CD56 (B, mag-
nification 350X) or with granzyme B (C, magnifica-
tion 500x), all detected in blue using alkaline phos-
phatase staining.
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also stained with the granzyme B mAb, although in some biopsies
a small number of cells (<10%) expressed only granzyme B.
The number of granzyme A and B positive cells detected in the
TEL fixed, paraffin embedded slides was three to five times higher
than that found in the double staining technique on acetone fixed,
fresh frozen tissue. This discrepancy probably resulted from a
difference in sensitivity between both techniques. Therefore, we
also performed a staining with granzyme B and CD3 on thin (2
xm) sequential paraffin embedded tissue sections. From these
experiments it was concluded that in the paraffin sections high
numbers of granzyme B positive cells were also expressing CD3.
Probably the amount of granzyme protein in these cells was too
low to be detected in the double staining on fresh frozen tissue.
However, in this way granzyme positive cells were also detected
which were CD3-negative. This latter is illustrated in Figure 1C,
where a glomerulus is infiltrated by numerous granzyme B
positive cells while the same area contains hardly any CD3
positive cells (Fig. 1D).
Discussion
Although the role of granzymes in the cytotoxic process is still
not elucidated, expression of these proteins by NK cells and
cytotoxic T lymphocytes correlates with the cytotoxic potency of
these cells in vitro [15—17]. The availability of specific mAbs
reacting with granzymes facilitates the evaluation of the role of
these cells in vivo. In this study we used these mAbs to study
granzyme expression by cells in renal allografts from patients
suffering from an acute cellular rejection. In only one patient with
histological signs of rejection a relatively low number of the
infiltrating cells expressed granzyme B, whereas no granzyme A
positive cells were found. The other patients with allograft
rejection, were all characterized by having high numbers of
granzyme A as well as granzyme B protein expressing lymphocytes
infiltrating the renal allograft tissue. In spite of the presence of a
marked inflammatory infiltrate, no granzyme positive cells were
found in several inflammatory, not transplant-related, renal dis-
eases. Only in one patient, with a renal adenocarcinoma, gran-
zyme positive cells were found in the tumor, which is consistent
with a role of cytotoxic lymphocytes in the immunologic response
to tumor cells. Therefore, granzyme expression by lymphocytes
infiltrating the kidneys seems to be rather specific for allograft
transplant rejection. Whether this expression is specifically related
to an rejection episode is more difficult to establish since no tissue
specimens, except for one, were available from patients with a
renal transplant without a rejection episode. Such specimens are,
for ethical reasons, hard to obtain. In one specimen from a patient
with a renal transplant without rejection, we found some gran-
zyme A and B positive cells in the absence of histological signs of
rejection. However, the number and intensity of granzyme posi-
tive cells was much lower compared to that of the patient group.
This may be a reflection of the existence of a 'low grade' of
immune activity in the allograft, independent on the presence of
rejection episodes. Although a good correlation existed in the
patient group studied between a clinical score for acute rejection
and either the BANFF classification or semiquantitative amount
of granzyme A and B expression, we think that study of a much
larger group of patients is required to establish such a possible
relationship with certainty.
Our results extend a recent study in which mRNA of granzyme
B gene was determined in patients with renal allograft rejection
using the PCR technique. Granzyme B gene expression was
almost exclusively confined to biopsies from patients with acute
cellular rejection compared to non-rejected allografts, whereas no
significant differences were found between rejection and non-
rejection samples regarding the gene transcripts of IL-113, IL-2,
IL-6, TNF-a and IL-2 receptor beta [24]. Similarly, our results
indicate that expression of granzyme B proteins, and in addition
also that of granzyme A, is associated with cellular allograft
rejection. Moreover, perform expressing lymphocytes could be
detected by immunohistochemical methods in a small group of
renal allograft patients showing acute allograft rejection [29, 30],
although others have shown that intragraft perform gene expres-
sion was found to be a less sensitive marker compared to that of
granzyme B gene expression [31].
Phenotypic analysis of cells infiltrating allograft tissues (for
example, the CD4:CD8 ratio) does not always provide reliable
information on the functional status of the graft itself [32].
Although florid rejection is readily identified by histological
parameters, virtually every allograft is infiltrated to some degree
by host lymphocytes. Furthermore, the cytotoxic cells present in
allograft tissues do not always represent functional killers. Expres-
sion of cytolytic mediators such as granzyme A and perform is
suppressed by corticosteroids and cyclosporin A [33, 34]. Heart
allografts showed minimal granzyme A positive cells after cyclo-
sporin A treatment, whether cellular infiltrates developed or not
[34]. All patients in our study received immunosuppressive drugs
consisting of corticosteroids as well as cyclosporin A. In spite of
this medication granzyme positive cells were found in all patients,
indicating that the immunosuppressive medication in these pa-
tients could not prevent the transcription and translation of
granzymes, apparently resulting in functional active cytotoxic
cells. At present we are investigating whether successful immuno-
suppressive treatment of renal allograft rejection is followed by
decreased expression of granzymes.
It is generally believed that rejection episodes of renal allo-
transplants are mediated by the cytotoxic attack of host lympho-
cytes via T cell receptor recognition of donor alloantigens, that is,
MHC class I and II. However, several cell adhesion molecules
(ICAM-1, VCAM-1) are increased on the vascular endothelium
and on the tubular system during allograft rejection [35, 36]. The
increase of these molecules enhances the susceptibility to T cell
and NK cell mediated lysis [1, 37, 38]. In agreement herewith,
most biopsies contained CD3 and CD3 granzyme positive
cytotoxic cells infiltrating the tubular walls, the peritubular capil-
laries and the glomeruli. Previously this was also observed for
perform positive cells in renal allograft rejection [30].
The granzyme positive infiltrating cytotoxic cell population
consisted predominantly of CD3CD56 NK cells and also in
some patients CD3 CD8 CTL, as determined by double
immunostaining techniques on fresh frozen tissue. This would
suggest that NK cells are the predominant cells expressing grail-
zymes in renal allograft rejection. However, the granzyme staining
on the paraffin embedded tissue slides appeared to be more
sensitive, and we estimated that the phenotype of about only 20%
of the cells positive for granzymes could be determined by double
staining techniques. To establish the phenotype of the other
granzyme-positive cells we performed CD3 and granzyme B
staining of serial paraffin-embedded sections. The results showed
that these granzyme positive cells were mainly CD3 positive and
probably represented CD3 CD8 CTL. These results indicate
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that during rejection of renal allotransplants the cells producing
the highest level of granzyme proteins are activated NK cells, and
that CTL express lower amount of these mediators.
These observations suggest a strong local production of IL-2
leading to the activation of CTL and NK cells into activated killer
cells (LAK), which may mediate non-MHC restricted cellular
cytotoxicity [37, 391. LAK cells have been isolated from renal
allograft tissue from patients with acute cellular rejection and are
able to kill both glomerular and tubular cells grown from the same
nephrectomy specimen without showing MHC antigen restriction
[39]. Interestingly, these LAKcells showed a similar lytic potential
for renal cells obtained from third party renal tissue [39]. Even
LAK cells obtained by stimulating peripheral blood mononuclear
cells with high dose of IL-2 were able to lyse normal kidney cells
[39—41]. In vitro, LAK cells not only mediate lysis of tubular cells,
but can also impair the function of kidney cell monolayers by
destroying the transepithelium resistance in the abscence of cell
lysis [40]. These in vitro phenomena may occur in vivo, as we
observed activated cytotoxic, that is, granzyme positive, cells
infiltrating the renal epithelial cells of the tubular wall. Although
the role of the different granzymes in the cytotoxic process is still
not elucidated [42—44], granzymes can mediate inflammatory
functions such as the breakdown of extracellular matrix proteins
and vascular basement membranes [45, 46], or activation of other
proteinases such as pro-urokinase [471. The release of these
proteases during the rejection episode could result in the destruc-
tion of the tight junctions between the tubular cells or in the
breakdown of other renal tissue components.
In conclusion, granzyme proteins are expressed by infiltrating
NK cells and CTLs in kidney allografts during acute cellular
rejection episode as detected by immunohistochemistry. Their
role in the pathogenesis of graft injuly and their relevance in
predicting or monitoring graft rejection remains to be established.
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Appendix Abbreviations
Abbreviations are: AP, alkaline phosphatase; CTL, cytotoxic T lympho-
cyte; FITC, fluorescein isothyocyanate; HRP, horseradish peroxidase;
mAb, monoclonal antibody; MHC, major histocompatibility complex; NK,
natural killer; PBS, phosphate-buffered saline, pH 7.4; PBS-B, PBS-1%
(wt/vol) bovine serum albumin; PBS-NHS, PBS-10% (vol/vol) normal
human serum; PCR, polymerase chain reaction; RT, room temperature;
TEL, Tellyesniczky.
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